- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Increase in Federal Approvals Uplifts Drug Companies
The Boston Globe reported that amid the sluggish economy, drug makers are happy about the Food and Drug Administration’s pace of drug approvals. Last year, the FDA approved 39 new treatments, which is higher than 2011’s 30.
The Boston Globe reported that amid the sluggish economy, drug makers are happy about the Food and Drug Administration’s pace of drug approvals. Last year, the FDA approved 39 new treatments, which is higher than 2011’s 30.
As quoted in the market news:
“It’s a very, very exciting time,” said Harry Glorikian, managing partner at Scientia Advisors, a life sciences consulting firm in Cambridge. “I don’t see any reason why it’s going to slow down.”
Boston-area companies at the conference this week — including ImmunoGen Inc. of Waltham, Biogen Idec Inc., based in Weston, and AVEO Pharmaceuticals Inc. of Cambridge — are awaiting FDA rulings on applications for drugs to treat conditions ranging from breast cancer to kidney cancer to multiple sclerosis. Companies from other parts of the country are seeking permission to start selling drugs for Parkinson’s disease, hospital-acquired pneumonia, and many other illnesses.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.